{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T09:41:37Z","timestamp":1723023697725},"reference-count":39,"publisher":"Kurume Medical Journal","issue":"1.2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kurume Med. J."],"published-print":{"date-parts":[[2023,6,30]]},"DOI":"10.2739\/kurumemedj.ms7012003","type":"journal-article","created":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T22:13:13Z","timestamp":1710799993000},"page":"39-45","source":"Crossref","is-referenced-by-count":0,"title":["Oral Colchicine and Low-Dose Aspirin Combination Therapy for Non-elderly, Non-severe, Early Time From Onset, Adult Outpatients with Coronavirus Disease 2019 (COVID-19) during \u201cThe Fifth Pandemic Wave\u201d in Japan"],"prefix":"10.2739","volume":"70","author":[{"given":"TETSUAKI","family":"INOKUCHI","sequence":"first","affiliation":[{"name":"Kurume Physicians Association (Kurume Naikaikai)"},{"name":"Inokuchi Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"TOMOKI","family":"HOMMA","sequence":"additional","affiliation":[{"name":"Kurume Physicians Association (Kurume Naikaikai)"},{"name":"Homma Cardiovascular Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"YASUHIKO","family":"KITASATO","sequence":"additional","affiliation":[{"name":"Kurume Physicians Association (Kurume Naikaikai)"},{"name":"JCHO Kurume General Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MAYU","family":"AKIYAMA","sequence":"additional","affiliation":[{"name":"JCHO Kurume General Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"AYAKO","family":"CHIKASUE","sequence":"additional","affiliation":[{"name":"JCHO Kurume General Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"YUUYA","family":"NISHII","sequence":"additional","affiliation":[{"name":"JCHO Kurume General Hospital"},{"name":"Division of Respirology, Neurology, and Rheumatology, Department of Medicine, Kurume University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SHIGEKI","family":"BAN","sequence":"additional","affiliation":[{"name":"Kurume Physicians Association (Kurume Naikaikai)"},{"name":"Ban Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"TAKEKI","family":"ADACHI","sequence":"additional","affiliation":[{"name":"Kurume Physicians Association (Kurume Naikaikai)"},{"name":"Adachi Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"AYA","family":"SONEZAKI","sequence":"additional","affiliation":[{"name":"JCHO Kurume General Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"HIROSHI","family":"MASUDA","sequence":"additional","affiliation":[{"name":"JCHO Kurume General Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"HIDEKI","family":"KAMEI","sequence":"additional","affiliation":[{"name":"JCHO Kurume General Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MIKI","family":"TAKENAKA","sequence":"additional","affiliation":[{"name":"JCHO Kurume General Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MAKI","family":"TANAKA","sequence":"additional","affiliation":[{"name":"JCHO Kurume General Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MASAKI","family":"OKAMOTO","sequence":"additional","affiliation":[{"name":"Division of Respirology, NHO Kyushu Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"TOMOAKI","family":"HOSHINO","sequence":"additional","affiliation":[{"name":"Division of Respirology, Neurology, and Rheumatology, Department of Medicine, Kurume University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"THE K-COCOA (KURUME-COVID-19 THERAPEUTIC PROGRAM BY COLCHICINE AND LOW-DOSE ASPIRIN) STUDY COLLABORATORS","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1445","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Tani-Sassa C, Iwasaki Y, Ichimura N, Nagano K, Takatsuki Y et al. Viral loads and profile of the patients infected with SARS-CoV-2 Delta, Alpha, or R.1 variants in Tokyo. J Med Virol 2022; 94:1707-1710.","DOI":"10.1002\/jmv.27479"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Gao SJ, Guo H, and Luo G. Omicron variant (B.1.1.529) of SARS-CoV-2, a global urgent public health alert! J Med Virol 2022; 94:1255-1256.","DOI":"10.1002\/jmv.27491"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Suzuki R, Yamasoba D, Kimura I, Wang L, Kishimoto M et al. Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant. Nature 2022; 603:700-705.","DOI":"10.1038\/s41586-022-04462-1"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Agarwal A, Rochwerg B, Lamontagne F, Siemieniuk RA, Agoritsas T et al. Update to living WHO guideline on drugs for COVID-19. BMJ 2021; 374:n2219.","DOI":"10.1136\/bmj.n2219"},{"key":"5","unstructured":"5. Japanese Ministry of Health, Labour and Welfare. Clinical management of patients with COVID-19; A guide for front-line healthcare workers, Version 2.1 (June 17, 2020). https:\/\/www.niph.go.jp\/h-crisis\/wp-content\/uploads\/2021\/01\/20210112112931_content_000646531.pdf."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Davies NG, Abbott S, Barnard RC, Jarvis CI, Kucharski AJ et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science 2021; 372:eabg3055.","DOI":"10.1126\/science.abg3055"},{"key":"7","unstructured":"7. Aleem A, Akbar Samad AB, and Slenker AK. Emerging variants of SARS-CoV-2 and novel therapeutics against coronavirus (COVID-19). In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Sheikh A, McMenamin J, Taylor B, Robertson C, and Public Health Scotland and the EAVE II Collaborators. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. Lancet 2021; 397:2461-2462.","DOI":"10.1016\/S0140-6736(21)01358-1"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Fisman DN and Tuite AR. Evaluation of the relative virulence of novel SARS-CoV-2 variants: a retrospective cohort study in Ontario, Canada. CMAJ 2021; 193:E1619-E1625.","DOI":"10.1503\/cmaj.211248"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Deftereos SG, Giannopoulos G, Vrachatis DA, Siasos GD, Giotaki SG et al. Effect of colchicine vs standard care on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with coronavirus disease 2019; the GRECCO-19 randomized clinical trial. JAMA Netw Open 2020; 3:e2013136.","DOI":"10.1001\/jamanetworkopen.2020.13136"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Tardif JC, Bouabdallaoui N, L\u2019Allier PL, Gaudet D, Shah B et al. Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled multicentre trial. Lancet Respir Med 2021; 9:924-932.","DOI":"10.1016\/S2213-2600(21)00222-8"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Salah HM and Mehta JL. Meta-analysis of the effect of colchicine on mortality and mechanical ventilation in COVID-19. Am J Cardiol 2021; 145:170-172.","DOI":"10.1016\/j.amjcard.2021.02.005"},{"key":"13","unstructured":"13. Kitasato Y, Imaoka H, Shinotsuka Y, Miyamoto A, Ishikawa S et al. Our clinical experience of using colchicine against the COVID-19 \u201c4th epidemic wave\u201d in Japan. Rinsho to Kenkyu 2021; 98:994-998. In Japanese."},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Chow JH, Khanna AK, Kethireddy S, Yamane D, Levine A et al. Aspirin use is associated with decreased mechanical ventilation, intensive care unit admission, and in-hospital mortality in hospitalized patients with coronavirus disease 2019. Anesth Analg 2021; 132:930-941.","DOI":"10.1213\/ANE.0000000000005292"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Thachil J, Tang N, Gando S, Falanga A, Cattaneo M et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost 2020; 18:1023-1026.","DOI":"10.1111\/jth.14810"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med 2020; 382:1564-1567.","DOI":"10.1056\/NEJMc2004973"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. The RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M et al. Dexamethasone in hospitalized patients with COVID-19. N Engl J Med 2021; 384:693-704.","DOI":"10.1056\/NEJMoa2021436"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Wong CKH, Lau KTK, Au ICH, Xiong X, Chung MSH et al. Optimal timing of remdesivir initiation in hospitalized COVID-19 patients administered with dexamethasone. Clin Infect Dis 2021; ciab728.","DOI":"10.1093\/cid\/ciab728"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR et al. Baricitinib plus remdesivir for hospitalized adults with COVID-19. N Engl J Med 2021; 384:795-807.","DOI":"10.1056\/NEJMoa2031994"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 2021; 397:1637-1645.","DOI":"10.1016\/S0140-6736(21)00676-0"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with COVID-19. N Engl J Med 2021; 384:238-251.","DOI":"10.1056\/NEJMoa2035002"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Razonable RR, Pawlowski C, O\u2019Horo JC, Arndt LL, Arndt R et al. Casirivimab-imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19. EClinicalMedicine 2021; 40:101102.","DOI":"10.1016\/j.eclinm.2021.101102"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Gupta A, Gonzalez-Rojas Y, Juarez E, Crespo Casal M, Moya J et al. Early treatment for COVID-19 with SARS-CoV-2 neutralizing antibody sotrovimab. N Engl J Med 2021; 385:1941-1950.","DOI":"10.1056\/NEJMoa2107934"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Khoo SH, Fitzgerald R, Fletcher T, Ewings S, Jaki T et al. Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study. J Antimicrob Chemother 2021; 76:3286-3295.","DOI":"10.1093\/jac\/dkab318"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Mahase E. COVID-19: Molnupiravir reduces risk of hospital admission or death by 50% in patients at risk, MSD reports. BMJ 2021; 375:n2422.","DOI":"10.1136\/bmj.n2422"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Mahase E. COVID-19: Pfizer\u2019s paxlovid is 89% effective in patients at risk of serious illness, company reports. BMJ 2021; 375:n2713.","DOI":"10.1136\/bmj.n2713"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W et al. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. N Engl J Med 2022; 386:1397-1408.","DOI":"10.1056\/NEJMoa2118542"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Mukae H, Yotsuyanagi H, Ohmagari N, Doi Y, Imamura T et al. Efficacy and Safety of Ensitrelvir in Patients With Mild-to-Moderate Coronavirus Disease 2019: The Phase 2b Part of a Randomized, Placebo-Controlled, Phase 2\/3 Study. Clin Infect Dis 2023; 76:1403-1411.","DOI":"10.1093\/cid\/ciac933"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Brunetti L, Diawara O, Tsai A, Firestein BL, Nahass RG et al. Colchicine to weather the cytokine storm in hospitalized patients with COVID-19. J Clin Med 2020; 9:2961.","DOI":"10.3390\/jcm9092961"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Downing S, Chauhan V, Chaudry IH, Galwankar S, Sharma P et al. Colchicine, aspirin, and montelukast \u2014 a case of successful combined pharmacotherapy for adult multisystem inflammatory syndrome in COVID-19. J Glob Infect Dis 2020; 12:221-224.","DOI":"10.4103\/jgid.jgid_296_20"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Thrupthi K, Ganti A, Acherjee T, Mehmood MA, and Vakde T. A rare case of acute pericarditis due to SARS-CoV-2 managed with aspirin and colchicine. Cureus 2021; 13:e12534.","DOI":"10.7759\/cureus.12534"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Kevorkian JP, Lopes A, S\u00e8ne D, Riveline JP, Vandiedonck C et al. Oral corticoid, aspirin, anticoagulant, colchicine, and furosemide to improve the outcome of hospitalized COVID-19 patients \u2014 the COCAA-COLA cohort study. J Infect 2021; 82:276-316.","DOI":"10.1016\/j.jinf.2021.02.008"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Toyoda K, Yasaka M, Uchiyama S, Nagao T, Gotoh J et al. Blood pressure levels and bleeding events during antithrombotic therapy: the Bleeding with Antithrombotic Therapy (BAT) Study. Stroke 2010; 41:1440-1444.","DOI":"10.1161\/STROKEAHA.110.580506"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. RECOVERY Collaborative Group. Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet Respir Med 2021; 9:1419-1426.","DOI":"10.1016\/S2213-2600(21)00435-5"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Mikolajewska A, Fischer AL, Piechotta V, Mueller A, Metzendorf MI et al. Colchicine for the treatment of COVID-19. Cochrane Database Syst Rev 2021; 10:CD015045.","DOI":"10.1002\/14651858.CD015045"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Absal\u00f3n-Aguilar A, Rull-Gabayet M, P\u00e9rez-Fragoso A, Mej\u00eda-Dom\u00ednguez NR, N\u00fa\u00f1ez-\u00c1lvarez C et al. Colchicine is safe though ineffective in the treatment of severe COVID-19: a randomized clinical trial (COLCHIVID). J Gen Intern Med 2022; 37:4-14.","DOI":"10.1007\/s11606-021-07203-8"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Mehta KG, Patel T, Chavda PD, and Patel P. Efficacy and safety of colchicine in COVID-19: a meta-analysis of randomised controlled trials. RMD Open 2021; 7:e001746.","DOI":"10.1136\/rmdopen-2021-001746"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. RECOVERY Collaborative Group. Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 2022; 399:143-151.","DOI":"10.1016\/S0140-6736(21)01825-0"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Connors JM, Brooks MM, Sciurba FC, Krishnan JA, Bledsoe JR et al. Effect of antithrombotic therapy on clinical outcomes in outpatients with clinically stable symptomatic COVID-19: the ACTIV-4B randomized clinical trial. JAMA 2021; 326:1703-1712.","DOI":"10.1001\/jama.2021.17272"}],"container-title":["The Kurume Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/kurumemedj\/70\/1.2\/70_MS7012003\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T05:05:40Z","timestamp":1720242340000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/kurumemedj\/70\/1.2\/70_MS7012003\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,30]]},"references-count":39,"journal-issue":{"issue":"1.2","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.2739\/kurumemedj.ms7012003","relation":{},"ISSN":["0023-5679","1881-2090"],"issn-type":[{"type":"print","value":"0023-5679"},{"type":"electronic","value":"1881-2090"}],"subject":[],"published":{"date-parts":[[2023,6,30]]},"article-number":"MS7012003"}}